Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00405743 · ClinicalTrials.gov registry record · Phase 1
A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies
A Phase 1 study, sponsored by Clavis Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 153
- Enrollment target
NCT00405743 is a Phase 1 study that has completed, run by Clavis Pharma. The registered enrollment target is 153 participants.
The verdict
NCT00405743, a Phase 1 study, has completed, sponsored by Clavis Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 153 participants
- Enrollment target
Study Summary
Patients with refractory or relapsed hematologic malignancies will receive CP-4055 intravenously(IV) on Day 1-5 every three weeks until complete response or disease worsening/progressing
Interventions
- DRUG CP-4055
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2006-05 |
| Est. Completion | 2010-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00405743
The ClinicalTrials.gov registry entry for NCT00405743 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 153 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Clavis Pharma, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CP-4055 is the first listed.
NCT00405743 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00405743 about?
NCT00405743 is a clinical study titled "A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies". Patients with refractory or relapsed hematologic malignancies will receive CP-4055 intravenously(IV) on Day 1-5 every three weeks until complete response or disease worsening/progressing
What is the current status of trial NCT00405743?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 153 participants. The study started on 2006-05. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00405743?
The interventions under investigation include: CP-4055 (DRUG).
Who is sponsoring clinical trial NCT00405743?
This trial is sponsored by Clavis Pharma, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.